Details
Stereochemistry | ACHIRAL |
Molecular Formula | C29H29F3N8O |
Molecular Weight | 562.5888 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CC2=CC=C(C=C2C(F)(F)F)C(=O)NC3=CC(NC4=NC=CC(=N4)C5=CC=CN=C5)=C(C)N=C3)CC1
InChI
InChIKey=BJCJYEYYYGBROF-UHFFFAOYSA-N
InChI=1S/C29H29F3N8O/c1-19-26(38-28-34-9-7-25(37-28)21-4-3-8-33-16-21)15-23(17-35-19)36-27(41)20-5-6-22(24(14-20)29(30,31)32)18-40-12-10-39(2)11-13-40/h3-9,14-17H,10-13,18H2,1-2H3,(H,36,41)(H,34,37,38)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20703259Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/20478851 | http://adisinsight.springer.com/drugs/800035564
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20703259
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/20478851 | http://adisinsight.springer.com/drugs/800035564
Flumatinib (HHGV678) is an orally bioavailable antineoplastic tyrosine kinase inhibitor. Flumatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. Flumatinib was extensively metabolized after oral administration, and the major metabolic pathways observed were amide hydrolysis, demethylation, oxidation, and glucuronide conjugation. It is in phase III clinical trials for the treatment of Chronic myeloid leukemia (in China).
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1862 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20703259 |
1.2 nM [IC50] | ||
Target ID: CHEMBL1913 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20703259 |
308.0 nM [IC50] | ||
Target ID: CHEMBL1936 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20703259 |
665.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance. | 2010 Oct |
|
[Effect of flumatinib mesylate on C-MYC, HIF-1α and VEGF in U226 line]. | 2013 Dec |
|
Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. | 2014 Jan |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01503502
400 mg once daily or 600 mg once daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18928591
Flumatinib of 10.0 micromol/L induced cell apoptosis of 40.06% and 33.32% in K562R and 32Dp210(T315I) cell lines
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 04:59:40 GMT 2023 , Edited by admin on Sat Dec 16 04:59:40 GMT 2023
|
||
|
NCI_THESAURUS |
C1967
Created by
admin on Sat Dec 16 04:59:40 GMT 2023 , Edited by admin on Sat Dec 16 04:59:40 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C138991
Created by
admin on Sat Dec 16 04:59:40 GMT 2023 , Edited by admin on Sat Dec 16 04:59:40 GMT 2023
|
PRIMARY | |||
|
46848036
Created by
admin on Sat Dec 16 04:59:40 GMT 2023 , Edited by admin on Sat Dec 16 04:59:40 GMT 2023
|
PRIMARY | |||
|
11831
Created by
admin on Sat Dec 16 04:59:40 GMT 2023 , Edited by admin on Sat Dec 16 04:59:40 GMT 2023
|
PRIMARY | |||
|
R4009Y24AI
Created by
admin on Sat Dec 16 04:59:40 GMT 2023 , Edited by admin on Sat Dec 16 04:59:40 GMT 2023
|
PRIMARY | |||
|
895519-90-1
Created by
admin on Sat Dec 16 04:59:40 GMT 2023 , Edited by admin on Sat Dec 16 04:59:40 GMT 2023
|
PRIMARY | |||
|
DB11904
Created by
admin on Sat Dec 16 04:59:40 GMT 2023 , Edited by admin on Sat Dec 16 04:59:40 GMT 2023
|
PRIMARY | |||
|
DTXSID60237779
Created by
admin on Sat Dec 16 04:59:40 GMT 2023 , Edited by admin on Sat Dec 16 04:59:40 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545413
Created by
admin on Sat Dec 16 04:59:40 GMT 2023 , Edited by admin on Sat Dec 16 04:59:40 GMT 2023
|
PRIMARY | |||
|
300000039112
Created by
admin on Sat Dec 16 04:59:40 GMT 2023 , Edited by admin on Sat Dec 16 04:59:40 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)